MX2009005011A - Imidazopirazinas como inhibidores de proteina quinasa. - Google Patents

Imidazopirazinas como inhibidores de proteina quinasa.

Info

Publication number
MX2009005011A
MX2009005011A MX2009005011A MX2009005011A MX2009005011A MX 2009005011 A MX2009005011 A MX 2009005011A MX 2009005011 A MX2009005011 A MX 2009005011A MX 2009005011 A MX2009005011 A MX 2009005011A MX 2009005011 A MX2009005011 A MX 2009005011A
Authority
MX
Mexico
Prior art keywords
compounds
methods
imidazopyrazines
protein kinase
kinase inhibitors
Prior art date
Application number
MX2009005011A
Other languages
English (en)
Inventor
M Arshad Siddiqui
Lianyun Zhao
Timothy J Guzi
David B Belanger
Patrick J Curran
Blake Hamann
Panduranga Adulla P Reddy
Praveen K Tadikonda
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39276164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009005011(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009005011A publication Critical patent/MX2009005011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En sus muchas modalidades, la presente invención provee una nueva clase de compuestos de imidazopirazina de la siguiente fórmula (1) (ver fórmula) como inhibidores de proteínas y/o Aurora quinasas, métodos de preparación de dichos compuestos, composiciones farmacéuticas que incluyen uno o más de dichos compuestos, métodos de preparación de formulaciones farmacéuticas que incluyen uno o más de dichos compuestos, y métodos de tratamiento, prevención, inhibición, o mejoría de una o más enfermedades asociadas con las proteínas o Aurora quinasas que utilizan dichos compuestos o composiciones farmacéuticas, tales como cáncer y leucemia.
MX2009005011A 2006-11-08 2007-11-06 Imidazopirazinas como inhibidores de proteina quinasa. MX2009005011A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85824406P 2006-11-08 2006-11-08
PCT/US2007/023329 WO2008057512A2 (en) 2006-11-08 2007-11-06 Imidazopyrazines as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2009005011A true MX2009005011A (es) 2009-05-20

Family

ID=39276164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005011A MX2009005011A (es) 2006-11-08 2007-11-06 Imidazopirazinas como inhibidores de proteina quinasa.

Country Status (11)

Country Link
US (1) US7511040B2 (es)
EP (1) EP2079746A2 (es)
JP (1) JP2010509328A (es)
CN (1) CN101589045A (es)
AR (1) AR063581A1 (es)
CA (1) CA2669465A1 (es)
CL (1) CL2007003212A1 (es)
MX (1) MX2009005011A (es)
PE (1) PE20080931A1 (es)
TW (1) TW200829588A (es)
WO (1) WO2008057512A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2010009985A2 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
JP5518062B2 (ja) * 2008-07-24 2014-06-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ オーロラキナーゼ阻害剤および抗悪性腫瘍剤を含む治療用組み合わせ
US8394802B2 (en) * 2008-09-19 2013-03-12 Nerviano Medical Sciences S.R.L. 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
NZ599597A (en) 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CA2793279A1 (en) * 2010-03-18 2011-09-22 Ulrich Klar Imidazopyrazines
EP2576560B1 (en) 2010-06-01 2015-09-30 Bayer Intellectual Property GmbH Substituted imidazopyrazines
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US20140187548A1 (en) * 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
ES2530802T3 (es) 2010-12-17 2015-03-06 Bayer Ip Gmbh Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos
CA2821819A1 (en) 2010-12-17 2012-06-21 Marcus Koppitz 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US8673905B2 (en) * 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
MX344600B (es) 2011-06-27 2016-12-20 Janssen Pharmaceutica Nv Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina.
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
RU2667058C2 (ru) 2012-07-09 2018-09-14 Янссен Фармацевтика Нв Ингибиторы фермента фосфодиэстеразы 10
SG11201610551TA (en) 2014-07-14 2017-01-27 Gilead Sciences Inc Combinations for treating cancers
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
US10562902B2 (en) 2015-08-13 2020-02-18 Beijing Hanmi Pharmaceutical Co., Ltd. IRAK4 inhibitor and use thereof
CN107056789B (zh) * 2017-04-21 2019-03-29 陈剑 具有取代吡嗪并咪唑类衍生物,其制备及其在医药上的应用
WO2022061155A1 (en) * 2020-09-17 2022-03-24 The Translational Genomics Research Institute Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026877A1 (en) * 2002-09-23 2004-04-01 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1945644A2 (en) * 2005-11-10 2008-07-23 Schering Corporation Imidazopyrazines as protein kinase inhibitors
US20070105864A1 (en) * 2005-11-10 2007-05-10 Schering Corporation Methods for inhibiting protein kinases

Also Published As

Publication number Publication date
CN101589045A (zh) 2009-11-25
JP2010509328A (ja) 2010-03-25
CL2007003212A1 (es) 2008-06-27
CA2669465A1 (en) 2008-05-15
TW200829588A (en) 2008-07-16
AR063581A1 (es) 2009-02-04
US7511040B2 (en) 2009-03-31
US20080139571A1 (en) 2008-06-12
PE20080931A1 (es) 2008-07-19
WO2008057512A3 (en) 2008-06-26
EP2079746A2 (en) 2009-07-22
WO2008057512A2 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
MX2009013729A (es) Imidazopirazinas como inhibidores de proteina quinasa.
IL260127B (en) mek inhibitors and methods of using them
WO2007058942A3 (en) Imidazopyrazines as protein kinase inhibitors
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
HK1112233A1 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors for the treatment of cancer
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
MX2009003734A (es) Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina.
MY149044A (en) Pyrazolopyrimidines - derivatives as cyclin dependent kinase inhibitors
MX2009011355A (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
TW200801008A (en) Protein kinase inhibitors
MX2009003733A (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
SG164368A1 (en) Treatment of cancer
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
DK1537116T3 (da) Pyrazolopyrimidiner egnede til behandling af cancersygdomme
MY162134A (en) Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2007058873A3 (en) Imidazopyrazines as cyclin depentend kinase inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
WO2007041358A8 (en) Substituted pyrazole compounds
WO2007044401A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs

Legal Events

Date Code Title Description
HH Correction or change in general